Potential pharmaceutic effect of Shilajit (mumie) on experimental osteoarthritis in rat
- 18 Downloads
Osteoarthritis (OA) is a worldwide joint disease with clinically loss of motion and pain in human. The conventional treatments are associated with essential side effects. In folk medicine, Shilajit is applied for treatment of arthritis and bone fractures. The present study evaluated effect of Shilajit on the osteoarthritis in rat model. Thirty-six adult male rats were randomly divided into two groups including OA and treated with Shilajit groups. OA was induced by injection of monosodium iodoacetate in the articular space of femorotibial joint. Aqueous extract of Shilajit was given to the treatment group by gavage as daily during experimental course until 21 days. The joint samples were investigated 7, 14, and 21 days post induction. The main macroscopic changes in the affected joints were swelling and congestion at early stages. Histopathologic study showed surface irregularity, erosion and fissures, necrotic chondrocytes, depletion of toluidine blue staining, and lysis of subchondral bone in both OA and Shilajit groups after 7 and 14 days. Synovium revealed synovial cells hyperplasia and inflammatory cells infiltration. Moderate to advanced OA was seen in both groups without significant difference. After 21 days, histopathologic scores of destructive damages and synovitis were reduced in the Shilajit group and showed significant difference in compare to OA group. The present study shows that aqueous extract of Shilajit decreased cartilage degenerative changes in knee osteoarthritis. Also, it reduced inflammatory reactions in synovial membrane.
KeywordsOsteoarthritis Monosodium iodoacetate Shilajit Toluidine blue Pathology
We would like to thank from Mr. Saeed Hassanzadeh for providing tissue sections.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All animals received human care in compliance with the Guide for Care and use of Laboratory. Animals published by the National Institutes of Health (NIH publication No. 85-23, revised 1985). The study was approved by the local ethics committee of our veterinary school.
- Frolova LN, Kiseleva TL (1996) Chemical composition of mumie and methods for determination of its authenticity and quality. Chem Pharm J 8:49–53Google Scholar
- Ismailova VN (1965) To a question about the dosage of mumie and special features of the healing of the fractures of the bones during its application. Med J Uzbekistan 9:69–70Google Scholar
- Kelginbaev NS, Sorokina VA, Stefanidu AG, Ismailova VN (1973) Treatment of long tubular bone fractures with mumie asil preparations in experiments and clinical conditions. Exp Surg Anesthes 4:31–35Google Scholar
- Korago AA. (1992). Introduction in biominerology. Nauka St. Petersburg. p 280Google Scholar
- Labban NY (2013) Shilajit, a novel regulator of bone/cartilage healing. Submitted to the faculty of the University Graduate School in partial fulfillment of the requirements for the degree. Doctor of Philosophy in the School of Dentistry, Indiana UniversityGoogle Scholar
- Maccioni RB, Farías GA, Rojo LE, Jiménez JM (2012) In search of therapeutic solutions for Alzheimer’s disease. In: Mantamadiotis T (ed) Brain WTGW-DaDotH, pp 125–150Google Scholar
- Naveen SV, Ahmad RE, Hui WJ, Suhaeb AM, Murali MR, Shanmugam R, Kamarul T (2014) Histology, glycosaminoglycan level and cartilage stiffness in monoiodoacetate-induced osteoarthritis: comparative analysis with anterior cruciate ligament transection in rat model and human osteoarthritis. Int J Med Sci 11(1):97–105CrossRefPubMedGoogle Scholar
- Rege AAA, Chowdhary AS (2014) Evaluation of Shilajit as putative HIV-protease inhibitor. Intern J Adv Res 2:154–157Google Scholar
- Rosenberg A (2002) Bones, joints, soft tissue tumors. In: Cotran R, Kuman V, Collins T (eds) Pathologic basis of disease. WB Saunders, Philadelphia, pp 1215–1268Google Scholar